MedTrace Logo

Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

NCT07313670 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2026-06-29

No results posted yet for this study

Summary

Although, hydrocortisone has shown promise in managing refractory shock, its role in early septic shock management remains unclear. This study aims to provide robust evidence on the clinical and hemodynamic outcomes of early hydrocortisone use in pediatric septic shock, contributing to standardized treatment protocols and improved survival rates.

Conditions

  • Septic Shock

Interventions

DRUG

Intravenous Hydrocortisone

Children will receive early intravenous hydrocortisone at 2 mg/kg/day divided every 6 hours, continued for 7 days or until resolution of shock.

DRUG

Standard care

The children will be managed by following standard institutional treatment protocol.

Sponsors & Collaborators

  • Muhammad Aamir Latif

    lead OTHER

Principal Investigators

  • Jawaria Ibrahim · Department of Pediatrics, Abbasi Shaheed Hospital Karachi, Pakistan

  • Ibrahim Shakoor, FCPS · Department of Pediatrics, Abbasi Shaheed Hospital Karachi, Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07313670 on ClinicalTrials.gov